ArticleAmerican journal of translational research2026
Development and validation of a nomogram for predicting grade 4 neutropenia in patients with breast cancer undergoing anthracycline-based chemotherapy.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGrade 4 neutropenia is a severe toxicity associated with anthracycline-based chemotherapy in patients with breast cancer. This study aimed to develop and validate a clinical prediction model for this adverse event during the first cycle of anthracycline-based chemotherapy.
methodsIn this multicenter retrospective study, female patients with breast cancer who received their first cycle of anthracycline-based chemotherapy between January 2017 and December 2023 were included. Patients were randomly assigned into training and internal validation cohorts in a 2:1 ratio. An independent external validation cohort comprised patients treated between January 2024 and December 2025. Predictors were selected using multivariable logistic regression with a backward stepwise approach, and a nomogram was constructed. Model performance was assessed in terms of discrimination, calibration, and clinical utility using decision curve analysis (DCA).
resultsA total of 672 patients were analyzed, with 518 in the training and internal validation cohort and 154 in the external validation cohort. Four independent predictors of grade 4 neutropenia were identified: age, body mass index (BMI), Ki67 index, and chemotherapy regimen. The model achieved area under the curve (AUC) values of 0.757, 0.759, and 0.731 in the training, internal validation, and external validation cohorts, respectively, demonstrating good discriminative ability. Calibration plots demonstrated satisfactory agreement between predicted and observed risks across all cohorts, and DCA confirmed the clinical utility of the model.
conclusionWe developed and externally validated a robust nomogram for predicting grade 4 neutropenia in patients with breast cancer undergoing their first cycle of anthracycline-based chemotherapy. This user-friendly tool may assist clinicians in identifying high-risk patients prior to treatment initiation, enabling timely preventive intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.